Neuronasal — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Neuronasal is a private, pre-revenue biotech focused on a patented intranasal delivery platform for brain-targeted therapeutics. Its core technology bypasses the blood-brain barrier to deliver the antioxidant drug N-acetylcysteine (NAC) directly to the brain, with initial applications in concussion (mTBI) and Parkinson's Disease. The company has demonstrated proof-of-concept in a human pilot trial, secured key patents and an NIH STTR grant, and is backed by investors including ATAI Life Sciences.

NeurologyTraumatology

Technology Platform

Patented intranasal (nose-to-brain) drug delivery platform designed to bypass the blood-brain barrier, enabling direct transport of therapeutics (e.g., N-acetylcysteine) to the brain via olfactory/trigeminal pathways. Includes method for dose calibration using Magnetic Resonance Spectroscopy (MRS).

Opportunities

The primary opportunity is addressing the massive, untreated market for concussion (mTBI), estimated at >$4B annually, with a first-in-class pharmacologic therapy.

A secondary major opportunity lies in developing a disease-modifying, neuroprotective treatment for Parkinson's Disease using a repurposed, safe drug delivered via a novel route.

Risk Factors

Key risks include the inherent uncertainty of clinical trials, where the platform's ability to deliver drug to the brain must translate into measurable patient efficacy.

Regulatory hurdles for a novel delivery method and competition from other neurology-focused biotechs and drug delivery technologies also pose significant challenges.

Competitive Landscape

Competition in mTBI is limited as there are no approved pharmacologic therapies, but other biotechs are exploring neuroprotective agents. In Parkinson's, competition is intense from both symptomatic and disease-modifying approaches. Neuronasal's primary competitive differentiation is its patented intranasal delivery platform for direct brain targeting of a repurposed drug.

More companies in Drug Delivery & Formulation →More companies in United States →